Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2005

View Archived Issues

PTC-124 begins phase II study for cystic fibrosis with FDA funding

Study to compare Xyotax and paclitaxel in women with advanced NSCLC

Exelixis and Bristol-Myers Squibb collaborate on LXR-targeting therapies

First milestone in Evotec and Takeda's Alzheimer's collaboration

Cephalon to acquire Zeneus Holdings

CA4P to be studied in combination with Avastin

BioDiem to study BDM-E in patients with diabetic macula edema

Inamed receives irrevocable offer and merger agreement from Allergan

First clinical trial of L-annamycin in relapsed and refractory ALL

PRTX-100 tested for first time in humans

Novelos to advance NOV-002 into pivotal phase III study for advanced NSCLC

Borean Pharma establishes proof-of-concept for TNF-alpha antagonist

New ROCK inhibitor displays antiangiogenic and antitumor effects

PK and tolerability profile of darunavir/low-dose ritonavir in humans

MK-0518: An effective short-term therapy in HIV-1 patients

Breast cancer responses not increased with tipifarnib-letrozole combination

ZK-EPO active in human breast cancer models

Scutellaria barbata extract (BZL-101) evaluated in phase I breast cancer trial

TAS-108 active, with acceptable toxicity, in postmenopausal breast cancer patients

Targeting Mcl-1 for leukemia

Xyrem launched in Germany for cataplexy in adult with narcolepsy

NDA filed for NRP-104 in ADHD

New analgesic agents reported in patent literature

Companies patent novel agents for gastrointestinal disorders

New agents reported with potential in treatment of Parkinson's disease and other disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...